Table 1.
Characteristics of Included Studies
| Study | Interventions Group/Control Group | N | Drug | Type of Surgery | Primary Outcome | JADAD Score |
|---|---|---|---|---|---|---|
| Yeap et al,14 2020 | PVB-S/PVB-C/TEA | 40/40/40 | 0.5% ropivacaine 30mL/0.2% ropivacaine 10 mL h−1/0.125% bupivacaine | Wedge, Lobectomy, Pleurodesis, Decortication, Mediastina | VAS, Opioid Usage | 3 |
| Ding et al,15 2018 | PVB-S/PVB-S/TEA | 36/34/32 | 0.5% ropivacaine 15mL/0.5% ropivacaine combined with dexmedetomidine 15mL/0.5% ropivacaine | Lobectomy | Opioid Usage, VRS, HR and MAP | 4 |
| Sylweriusz et al,16 2016 | PVB-S/TEA | 26/25 | 0.25% bupivacaine 20mL/0.25% bupivacaine | Lobectomy | VAS, Opioid Usage | 4 |
| Huang et al,17 2020 | PVB-C/PVB-C/TEA | 45/32/39 | 0.25% ropivacaine 0.25mg kg−1 h−1/0.25% ropivacaine 0.25mg kg−1 h−1/0.25% ropivacaine | Thoracoscopic surgery for lung cancer | Opioid Usage, NRS, HR and MAP | 4 |
| Okajima et al,18 2014 | PVB-C/TEA | 36/33 | 0.1% ropivacaine 6mL h−1/0.25–0.375% ropivacaine | Lobectomy Segmentectomy Wedge resection | VRS | 5 |